Your browser doesn't support javascript.
loading
A web-based survey on the occurrence of emotional blunting in patients with major depressive disorder in Japan: Patient perceptions and attitudes.
Kikuchi, Toshiaki; Iga, Jun-Ichi; Oosawa, Masato; Hoshino, Tatsuya; Moriguchi, Yoshiya; Izutsu, Miwa.
Affiliation
  • Kikuchi T; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
  • Iga JI; Department of Neuropsychiatry, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.
  • Oosawa M; Japan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo, Japan.
  • Hoshino T; Japan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo, Japan.
  • Moriguchi Y; Medical Affairs, Lundbeck Japan K.K., Tokyo, Japan.
  • Izutsu M; Japan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo, Japan.
Neuropsychopharmacol Rep ; 44(2): 321-332, 2024 Jun.
Article in En | MEDLINE | ID: mdl-38616339
ABSTRACT

AIMS:

To determine the prevalence and impact of emotional blunting (EB) in patients with major depressive disorder (MDD) in Japan, and identify treatment needs for EB using patients' perceptions and attitudes.

METHODS:

Eligible patients in Japan (aged 18-59 years) who reported a diagnosis of MDD and antidepressant medication use for >3 months were eligible to complete an online survey. The primary outcome was the prevalence of EB, self-reported using a validated screening question. Secondary outcomes included the correlation between EB symptoms (measured by the Oxford Depression Questionnaire [ODQ]) and scores on the Patient Health Questionnaire 9-item (PHQ-9), Generalized Anxiety Disorder 7-item (GAD-7), Work and Social Adjustment Scale (WSAS), and the EuroQol 5-Dimension 5-Levels questionnaire (EQ-5D-5L). Descriptive questions were used to explore patients' perceptions and attitudes toward EB.

RESULTS:

In total, 3376 patients were included in the analysis (56% male; 48% aged 50-59 years). Overall, 67.1% of patients self-reported symptoms of EB, with 10% rating these as severe. The mean (SD) ODQ total score was 78.2 (21.5), which increased with worsening EB symptoms. There were correlations between ODQ total scores and the PHQ-9, GAD-7, WSAS, and EQ-5D-5L scores (correlation coefficients 0.67, 0.55, 0.56, -0.51, respectively; all p < 0.0001). Descriptive analyses showed that one-third of patients reporting EB symptoms did not tell their physician, with two-thirds finding these symptoms distressing and likely to affect recovery.

CONCLUSION:

EB is an important clinical issue in Japan that needs to be considered alongside functional recovery when managing treatment of patients with MDD.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Internet / Depressive Disorder, Major Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: En Journal: Neuropsychopharmacol Rep Year: 2024 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Internet / Depressive Disorder, Major Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: En Journal: Neuropsychopharmacol Rep Year: 2024 Document type: Article Affiliation country: Country of publication: